View on GitHub

This release contains updates to the draft version of the database. EGFR TKD activating variants was introduced as a biomarker and associated with regulatory approvals from the European Medicines Agency (EMA) and Health Canada (HC). No additional genomic knowledge statements were added with this release, though several were modified.

Database content updates

Added entries:

  • (EMA, HC) EGFR TKD activating variants and response to gefitinib for patients with non-small cell lung cancer.

Revised entries:

  • (FDA) A description was previously not written for Statements associated with Indication ind:fda.kadcyla:0.
  • (FDA) The text for ind:fda.augtyro:1 was revised to resolve typos.
  • (HSE) The URLs were updated for all documents originating from Ireland’s Health Service Executive (HSE) to reflect their new website.
  • (HSE) ids associated with treatment regimen “P0567” from the HSE were updated to be “P00567”.
  • Biomarker names for EGFR, ERBB2, and ESR1 oncogenic variants were renamed to “activating variants” to align with the scope of the associated regulatory approvals.

New features

  • Badges in the moalmanac-db README are now hard coded and do not rely on an API request to render.